Proteomic subtypes of AML identified by similarity network clustering. (A) The discrimination of 8 proteomic subtypes (S1-S8) based on the SNF method. (B) Sankey plot indicating the relationship between the established proteomic subtypes and entities defined by the WHO and FAB classification. (C) Heat map of clinical features, cytogenetic groups, and recurrent gene fusions and mutations in AML, which are classified into diverse functional groups.3 Each column represents a patient, which is arranged according to the proteomic clusters (S1-S8). “FLT3” refers to FLT3 mutations other than FLT3-ITD, including FLT3-TKD and other site mutations. (D) The proportional distribution of age groups in S1 to S8 subtypes. (E-F) Kaplan-Meier curves for OS (E) and EFS (F) of patients with AML stratified by the 8 proteomic subtypes. GEP, gene expression profiling; HGB, hemoglobin; NOS, not otherwise specified; WBC, white blood cell count.
